Inceptor Bio

Inceptor Bio is a private, clinical-stage biotech targeting the significant unmet need in solid tumor oncology with its innovative OUTLAST™ cell therapy platform. The company's technology conditions T cells during manufacturing to enhance their persistence, metabolic fitness, and resistance to exhaustion, aiming to achieve durable responses where current CAR-T therapies have struggled. With a lead program, IB-T101, advancing in the clinic and a seasoned leadership team with experience in cell therapy and company building, Inceptor is positioning itself as a key player in the next wave of cell therapies for solid cancers.

OUTLAST™ platform - a manufacturing process that metabolically reprograms T cells and NK cells by conditioning them in environments that mimic the hostile tumor microenvironment (TME), aiming to enhance persistence, metabolic fitness, and resistance to exhaustion.

Inceptor Bio competes in the crowded and rapidly evolving field of solid tumor cell therapy. Competitors include other biotechs developing armored CAR-Ts (e.g., with cytokine engineering, dominant-negative receptors), TCR-based therapies, and NK cell therapies, as well as large pharma with major immuno-oncology divisions. Differentiation hinges on proving the superiority of its metabolic reprogramming approach in clinical trials.